<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01261793</url>
  </required_header>
  <id_info>
    <org_study_id>SL0010</org_study_id>
    <secondary_id>2010-018565-26</secondary_id>
    <nct_id>NCT01261793</nct_id>
  </id_info>
  <brief_title>Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)</brief_title>
  <acronym>EMBODY2</acronym>
  <official_title>A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to confirm the clinical efficacy of epratuzumab in the
      treatment of subjects with Systemic Lupus Erythematosus (SLE).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percent of Subjects Meeting Treatment Response Criteria at Week 48 According to a Combined Response Index</measure>
    <time_frame>At Week 48</time_frame>
    <description>Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set (FAS). The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) - no worsening compared to study entry, physician's global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percent of Subjects Meeting Treatment Response Criteria at Week 24 According to a Combined Response Index</measure>
    <time_frame>At Week 24</time_frame>
    <description>Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set (FAS). The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) - no worsening compared to study entry, physician's global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percent of Subjects Meeting Treatment Response Criteria at Week 12 According to a Combined Response Index</measure>
    <time_frame>At Week 12</time_frame>
    <description>Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set (FAS). The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) - no worsening compared to study entry, physician's global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percent of Subjects Meeting Treatment Response Criteria at Week 36 According to a Combined Response Index</measure>
    <time_frame>At Week 36</time_frame>
    <description>Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set (FAS). The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) - no worsening compared to study entry, physician's global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Corticosteroid Dose at Week 24</measure>
    <time_frame>At Week 24</time_frame>
    <description>Participants were grouped into 4 categories: Dose decreased by &gt;50%, Dose decreased &gt;0% to ≤50%, No change in dose and Dose increased or missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Corticosteroid Dose at Week 48</measure>
    <time_frame>At Week 48</time_frame>
    <description>Participants were grouped into 4 categories: Dose decreased by &gt;50%, Dose decreased &gt;0% to ≤50%, No change in dose and Dose increased or missing data.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">791</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Placebo (Weekly infusion)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epratuzumab 600 mg per week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12 week treatment cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epratuzumab 1200 mg every other week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles</description>
    <arm_group_label>Epratuzumab 1200 mg every other week</arm_group_label>
    <arm_group_label>Placebo (Weekly infusion)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epratuzumab</intervention_name>
    <description>600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles</description>
    <arm_group_label>Epratuzumab 600 mg per week</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epratuzumab</intervention_name>
    <description>1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles</description>
    <arm_group_label>Epratuzumab 1200 mg every other week</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive antinuclear antibodies (ANA) at Screening (Visit 1)

          -  Current clinical diagnosis of Systemic Lupus Erythematosus (SLE) by American College
             of Rheumatology (ACR) criteria such that at least 4 of the 11 criteria are met

          -  Active moderate to severe SLE activity as demonstrated by the British Isles Lupus
             Assessment Group Index (BILAG)

          -  Active moderate to severe SLE disease as demonstrated by SLE disease activity index
             (SLEDAI) total score

          -  On stable SLE treatment regimen, including mandatory corticosteroids and
             immunosuppressants or antimalarials

        Exclusion Criteria:

          -  Subjects who are breastfeeding, pregnant, or plan to become pregnant

          -  Subjects with active, severe SLE disease activity which involves the renal system

          -  Subjects with active, severe, neuropsychiatric SLE, defined as any neuropsychiatric
             element scoring BILAG level A disease.

          -  Subjects with the evidence of an immunosuppressive state

          -  Subjects who, in the opinion of the investigator, are at a particularly high risk of
             significant infection

          -  History of malignant cancer, except the following treated cancers: cervical carcinoma
             in situ, basal cell carcinoma, or dermatological squamous cell carcinoma.

          -  Subjects receiving any live vaccination within the 8 weeks prior to screening (Visit
             1).

          -  Subjects with history of infections, including but not limited to concurrent acute or
             chronic viral hepatitis B or C

          -  Subjects with substance abuse or dependence or other relevant concurrent medical
             condition

          -  Subjects with history of thromboembolic events within 1 year of screening Visit.

          -  Subjects with significant hematologic abnormalities

          -  Subject has received treatment with other anti- B cell antibodies within 12 months
             prior to screening (visit 1)

          -  Subject use of oral anticoagulant (not including) nonsteroidal anti-inflammatory drugs
             (NSAIDs) within 12 weeks prior to screening (Visit 1)

          -  Subject has previously participated in this study or has previously received
             epratuzumab treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>539</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>557</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>515</name>
      <address>
        <city>Hemet</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>544</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>550</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>548</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>589</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>531</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>558</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>594</name>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>532</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>514</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>533</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>518</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>585</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>538</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>537</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>587</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>590</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>543</name>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>592</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>576</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>572</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>554</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>513</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>599</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>575</name>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>549</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>596</name>
      <address>
        <city>Nashua</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>593</name>
      <address>
        <city>Clifton</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>568</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>551</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>553</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>545</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>577</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>559</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>547</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>561</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>535</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>598</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>571</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>574</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>570</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>541</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>563</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>562</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>552</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>534</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>954</name>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>956</name>
      <address>
        <city>Campinas</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>955</name>
      <address>
        <city>Goiânia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>950</name>
      <address>
        <city>Juiz de Fora</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>952</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>506</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>507</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>508</name>
      <address>
        <city>Rimouski</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502</name>
      <address>
        <city>Hamilton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>500</name>
      <address>
        <city>London</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>504</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>517</name>
      <address>
        <city>Victoria</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>613</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>618</name>
      <address>
        <city>Limoges Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>617</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>614</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>616</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>628</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>633</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>636</name>
      <address>
        <city>Dessau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>637</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>632</name>
      <address>
        <city>Herne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>629</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>625</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>626</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>634</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>627</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>639</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>631</name>
      <address>
        <city>Zerbst</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>712</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>716</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>718</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>717</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>711</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>715</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>713</name>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>852</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>853</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>648</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>647</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>646</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>978</name>
      <address>
        <city>Cuauhtémoc</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>976</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>982</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>981</name>
      <address>
        <city>Torreon</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>743</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>744</name>
      <address>
        <city>Czestochowa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>752</name>
      <address>
        <city>Elblag</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>745</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>746</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>748</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>750</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>742</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>747</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>751</name>
      <address>
        <city>Ustron</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>749</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>757</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>758</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>760</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>759</name>
      <address>
        <city>Constanta</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>756</name>
      <address>
        <city>Galati</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>761</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>778</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>780</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>779</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>901</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>902</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>903</name>
      <address>
        <city>Stellenbosch</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>661</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>660</name>
      <address>
        <city>Getafe</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>662</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>664</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>663</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>659</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>791</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>790</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>794</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>797</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>792</name>
      <address>
        <city>Luhansk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>793</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>796</name>
      <address>
        <city>Vinnytsya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>677</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>678</name>
      <address>
        <city>Christchurch</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>679</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>December 14, 2010</study_first_submitted>
  <study_first_submitted_qc>December 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2010</study_first_posted>
  <results_first_submitted>May 30, 2018</results_first_submitted>
  <results_first_submitted_qc>June 4, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 29, 2018</results_first_posted>
  <disposition_first_submitted>January 12, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>January 12, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 5, 2016</disposition_first_posted>
  <last_update_submitted>August 31, 2018</last_update_submitted>
  <last_update_submitted_qc>August 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lupus</keyword>
  <keyword>Monoclonal antibody</keyword>
  <keyword>B-Cell immunotherapy</keyword>
  <keyword>Epratuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epratuzumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study started to enroll patients in December 2010 and concluded in June 2015.</recruitment_details>
      <pre_assignment_details>Participant Flow refers to the Randomized Set (RS).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Weekly (RS)</title>
          <description>Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles</description>
        </group>
        <group group_id="P2">
          <title>Epratuzumab 1200 mg Every Other Week (RS)</title>
          <description>1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles</description>
        </group>
        <group group_id="P3">
          <title>Epratuzumab 600 mg Weekly (RS)</title>
          <description>600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12 week treatment cycles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="263"/>
                <participants group_id="P2" count="262"/>
                <participants group_id="P3" count="266"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="178"/>
                <participants group_id="P2" count="171"/>
                <participants group_id="P3" count="184"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="91"/>
                <participants group_id="P3" count="82"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient non-availability</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Suspected pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient pregnant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Outside the study area</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of efficacy &amp; patient not available</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient withdrew after cardiology visit</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomization error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient unable to start IV line</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Characteristics refers to the Safety Set (SS).</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Weekly (SS)</title>
          <description>Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles</description>
        </group>
        <group group_id="B2">
          <title>Epratuzumab 1200 mg Every Other Week (SS)</title>
          <description>1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles</description>
        </group>
        <group group_id="B3">
          <title>Epratuzumab 600 mg Weekly (SS)</title>
          <description>600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12 week treatment cycles</description>
        </group>
        <group group_id="B4">
          <title>Total Title</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="263"/>
            <count group_id="B2" value="261"/>
            <count group_id="B3" value="264"/>
            <count group_id="B4" value="788"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="254"/>
                    <measurement group_id="B2" value="257"/>
                    <measurement group_id="B3" value="254"/>
                    <measurement group_id="B4" value="765"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.1" spread="11.8"/>
                    <measurement group_id="B2" value="40.8" spread="11.5"/>
                    <measurement group_id="B3" value="41.2" spread="12.7"/>
                    <measurement group_id="B4" value="41.0" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="245"/>
                    <measurement group_id="B2" value="247"/>
                    <measurement group_id="B3" value="245"/>
                    <measurement group_id="B4" value="737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percent of Subjects Meeting Treatment Response Criteria at Week 48 According to a Combined Response Index</title>
        <description>Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set (FAS). The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) - no worsening compared to study entry, physician's global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes.</description>
        <time_frame>At Week 48</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all subjects in the Randomized Set (RS) who had received at least 1 partial dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Weekly (FAS)</title>
            <description>Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles</description>
          </group>
          <group group_id="O2">
            <title>Epratuzumab 1200 mg Every Other Week (FAS)</title>
            <description>1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles</description>
          </group>
          <group group_id="O3">
            <title>Epratuzumab 600 mg Weekly (FAS)</title>
            <description>600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12 week treatment cycles</description>
          </group>
        </group_list>
        <measure>
          <title>The Percent of Subjects Meeting Treatment Response Criteria at Week 48 According to a Combined Response Index</title>
          <description>Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set (FAS). The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) - no worsening compared to study entry, physician's global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes.</description>
          <population>The Full Analysis Set (FAS) consisted of all subjects in the Randomized Set (RS) who had received at least 1 partial dose of the study drug.</population>
          <units>Percentage of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5"/>
                    <measurement group_id="O2" value="34.1"/>
                    <measurement group_id="O3" value="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.899</p_value>
            <p_value_desc>p-values for the comparison of treatment groups have been calculated using logistic regression with factors for treatment, pooled region, and baseline disease status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.024</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.710</ci_lower_limit>
            <ci_upper_limit>1.477</ci_upper_limit>
            <estimate_desc>Odds ratio: Epratuzumab/Placebo calculated using logistic regression with factors for treatment, pooled region, and baseline disease status.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.716</p_value>
            <p_value_desc>p-values for the comparison of treatment groups have been calculated using logistic regression with factors for treatment, pooled region, and baseline disease status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.070</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.743</ci_lower_limit>
            <ci_upper_limit>1.539</ci_upper_limit>
            <estimate_desc>Odds ratio: Epratuzumab/Placebo calculated using logistic regression with factors for treatment, pooled region, and baseline disease status.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percent of Subjects Meeting Treatment Response Criteria at Week 24 According to a Combined Response Index</title>
        <description>Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set (FAS). The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) - no worsening compared to study entry, physician's global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes.</description>
        <time_frame>At Week 24</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all subjects in the Randomized Set (RS) who had received at least 1 partial dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Weekly (FAS)</title>
            <description>Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles</description>
          </group>
          <group group_id="O2">
            <title>Epratuzumab 1200 mg Every Other Week (FAS)</title>
            <description>1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles</description>
          </group>
          <group group_id="O3">
            <title>Epratuzumab 600 mg Weekly (FAS)</title>
            <description>600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12 week treatment cycles</description>
          </group>
        </group_list>
        <measure>
          <title>The Percent of Subjects Meeting Treatment Response Criteria at Week 24 According to a Combined Response Index</title>
          <description>Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set (FAS). The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) - no worsening compared to study entry, physician's global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes.</description>
          <population>The Full Analysis Set (FAS) consisted of all subjects in the Randomized Set (RS) who had received at least 1 partial dose of the study drug.</population>
          <units>Percentage of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3"/>
                    <measurement group_id="O2" value="33.0"/>
                    <measurement group_id="O3" value="43.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percent of Subjects Meeting Treatment Response Criteria at Week 12 According to a Combined Response Index</title>
        <description>Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set (FAS). The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) - no worsening compared to study entry, physician's global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes.</description>
        <time_frame>At Week 12</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all subjects in the Randomized Set (RS) who had received at least 1 partial dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Weekly (FAS)</title>
            <description>Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles</description>
          </group>
          <group group_id="O2">
            <title>Epratuzumab 1200 mg Every Other Week (FAS)</title>
            <description>1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles</description>
          </group>
          <group group_id="O3">
            <title>Epratuzumab 600 mg Weekly (FAS)</title>
            <description>600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12 week treatment cycles</description>
          </group>
        </group_list>
        <measure>
          <title>The Percent of Subjects Meeting Treatment Response Criteria at Week 12 According to a Combined Response Index</title>
          <description>Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set (FAS). The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) - no worsening compared to study entry, physician's global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes.</description>
          <population>The Full Analysis Set (FAS) consisted of all subjects in the Randomized Set (RS) who had received at least 1 partial dose of the study drug.</population>
          <units>Percentage of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0"/>
                    <measurement group_id="O2" value="32.2"/>
                    <measurement group_id="O3" value="40.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percent of Subjects Meeting Treatment Response Criteria at Week 36 According to a Combined Response Index</title>
        <description>Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set (FAS). The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) - no worsening compared to study entry, physician's global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes.</description>
        <time_frame>At Week 36</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all subjects in the Randomized Set (RS) who had received at least 1 partial dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Weekly (FAS)</title>
            <description>Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles</description>
          </group>
          <group group_id="O2">
            <title>Epratuzumab 1200 mg Every Other Week (FAS)</title>
            <description>1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles</description>
          </group>
          <group group_id="O3">
            <title>Epratuzumab 600 mg Weekly (FAS)</title>
            <description>600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12 week treatment cycles</description>
          </group>
        </group_list>
        <measure>
          <title>The Percent of Subjects Meeting Treatment Response Criteria at Week 36 According to a Combined Response Index</title>
          <description>Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set (FAS). The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) - no worsening compared to study entry, physician's global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes.</description>
          <population>The Full Analysis Set (FAS) consisted of all subjects in the Randomized Set (RS) who had received at least 1 partial dose of the study drug.</population>
          <units>Percentage of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7"/>
                    <measurement group_id="O2" value="33.0"/>
                    <measurement group_id="O3" value="36.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Corticosteroid Dose at Week 24</title>
        <description>Participants were grouped into 4 categories: Dose decreased by &gt;50%, Dose decreased &gt;0% to ≤50%, No change in dose and Dose increased or missing data.</description>
        <time_frame>At Week 24</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all subjects in the Randomized Set (RS) who had received at least 1 partial dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Weekly (FAS)</title>
            <description>Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles</description>
          </group>
          <group group_id="O2">
            <title>Epratuzumab 1200 mg Every Other Week (FAS)</title>
            <description>1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles</description>
          </group>
          <group group_id="O3">
            <title>Epratuzumab 600 mg Weekly (FAS)</title>
            <description>600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12 week treatment cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Corticosteroid Dose at Week 24</title>
          <description>Participants were grouped into 4 categories: Dose decreased by &gt;50%, Dose decreased &gt;0% to ≤50%, No change in dose and Dose increased or missing data.</description>
          <population>The Full Analysis Set (FAS) consisted of all subjects in the Randomized Set (RS) who had received at least 1 partial dose of the study drug.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose decreased by &gt;50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="0"/>
                    <measurement group_id="O2" value="10.0" spread="0"/>
                    <measurement group_id="O3" value="8.7" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose decreased &gt;0% to ≤50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" spread="0"/>
                    <measurement group_id="O2" value="18.0" spread="0"/>
                    <measurement group_id="O3" value="18.2" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change in dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.3" spread="0"/>
                    <measurement group_id="O2" value="46.7" spread="0"/>
                    <measurement group_id="O3" value="52.7" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose increased or missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2" spread="0"/>
                    <measurement group_id="O2" value="25.3" spread="0"/>
                    <measurement group_id="O3" value="20.5" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Corticosteroid Dose at Week 48</title>
        <description>Participants were grouped into 4 categories: Dose decreased by &gt;50%, Dose decreased &gt;0% to ≤50%, No change in dose and Dose increased or missing data.</description>
        <time_frame>At Week 48</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all subjects in the Randomized Set (RS) who had received at least 1 partial dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Weekly (FAS)</title>
            <description>Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles</description>
          </group>
          <group group_id="O2">
            <title>Epratuzumab 1200 mg Every Other Week (FAS)</title>
            <description>1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles</description>
          </group>
          <group group_id="O3">
            <title>Epratuzumab 600 mg Weekly (FAS)</title>
            <description>600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12 week treatment cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Corticosteroid Dose at Week 48</title>
          <description>Participants were grouped into 4 categories: Dose decreased by &gt;50%, Dose decreased &gt;0% to ≤50%, No change in dose and Dose increased or missing data.</description>
          <population>The Full Analysis Set (FAS) consisted of all subjects in the Randomized Set (RS) who had received at least 1 partial dose of the study drug.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose decreased by &gt;50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="0"/>
                    <measurement group_id="O2" value="13.8" spread="0"/>
                    <measurement group_id="O3" value="14.8" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose decreased &gt;0% to ≤50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" spread="0"/>
                    <measurement group_id="O2" value="13.4" spread="0"/>
                    <measurement group_id="O3" value="15.9" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change in dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7" spread="0"/>
                    <measurement group_id="O2" value="35.6" spread="0"/>
                    <measurement group_id="O3" value="36.7" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose increased or missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9" spread="0"/>
                    <measurement group_id="O2" value="37.2" spread="0"/>
                    <measurement group_id="O3" value="32.6" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent Adverse Events (TEAEs) were collected throughout the study (on or after first infusion of study drug and within 75 days of the last infusion), for an average of 4.5 years (starting in December 2010 and concluding in June 2015). The Safety Set will be utilized for TEAE reporting.</time_frame>
      <desc>The Safety Set (SS) consisted of all subjects in the Randomized Set (RS) who had received at least 1 partial dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Weekly (SS)</title>
          <description>Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles</description>
        </group>
        <group group_id="E2">
          <title>Epratuzumab 1200 mg Every Other Week (SS)</title>
          <description>1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles</description>
        </group>
        <group group_id="E3">
          <title>Epratuzumab 600 mg Weekly (SS)</title>
          <description>600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12 week treatment cycles</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA17.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="261"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Antiphospholipid syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Lupus myocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Talipes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Necrotising retinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Retinal degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Reflux gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hypomotility</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="261"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus chorioretinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus viraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Dermatitis infected</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Eye infection toxoplasmal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Post lumbar puncture syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="263"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="261"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Patellofemoral pain syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Lupus encephalitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Vasculitis cerebral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Noninfectious myelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Pregnancy on contraceptive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Generalised anxiety disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Lupus nephritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Lupus pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Lupus pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cutaneous lupus erythematosus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Cutaneous vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Raynaud's phenomenon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA17.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="145" subjects_at_risk="261"/>
                <counts group_id="E3" subjects_affected="158" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="51" subjects_affected="36" subjects_at_risk="263"/>
                <counts group_id="E2" events="41" subjects_affected="32" subjects_at_risk="261"/>
                <counts group_id="E3" events="38" subjects_affected="25" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="24" subjects_affected="19" subjects_at_risk="263"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="261"/>
                <counts group_id="E3" events="41" subjects_affected="25" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="263"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="261"/>
                <counts group_id="E3" events="23" subjects_affected="16" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="263"/>
                <counts group_id="E2" events="31" subjects_affected="15" subjects_at_risk="261"/>
                <counts group_id="E3" events="18" subjects_affected="15" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="263"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="261"/>
                <counts group_id="E3" events="18" subjects_affected="13" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="46" subjects_affected="37" subjects_at_risk="263"/>
                <counts group_id="E2" events="49" subjects_affected="38" subjects_at_risk="261"/>
                <counts group_id="E3" events="47" subjects_affected="37" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="66" subjects_affected="44" subjects_at_risk="263"/>
                <counts group_id="E2" events="45" subjects_affected="37" subjects_at_risk="261"/>
                <counts group_id="E3" events="54" subjects_affected="38" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="263"/>
                <counts group_id="E2" events="23" subjects_affected="15" subjects_at_risk="261"/>
                <counts group_id="E3" events="31" subjects_affected="24" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="23" subjects_affected="19" subjects_at_risk="263"/>
                <counts group_id="E2" events="17" subjects_affected="12" subjects_at_risk="261"/>
                <counts group_id="E3" events="23" subjects_affected="20" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="263"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="261"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="263"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="261"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="68" subjects_affected="42" subjects_at_risk="263"/>
                <counts group_id="E2" events="39" subjects_affected="29" subjects_at_risk="261"/>
                <counts group_id="E3" events="50" subjects_affected="33" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="263"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="261"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="263"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="261"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="263"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="261"/>
                <counts group_id="E3" events="19" subjects_affected="16" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="263"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="261"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UCB</name_or_title>
      <organization>Care</organization>
      <phone>+1844599 ext 2273</phone>
      <email>UCBCares@ucb.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

